Leeds Assessment of Neuropathic Symptoms and Signs (LANSS)
Objective[edit | edit source]
The LANSS was developed to provide a simple clinical tool that can be used to identify pain of predominantly neuropathic origin, thus distinguishing between neuropathic pain and nociceptive pain. By identifying neuropathic pain mechanisms, more individualised treatment can follow. The LANSS was developed in 2001, and a self-report version, the S-LANSS was developed in 2005.
Intended Population[edit | edit source]
The LANSS can be used in any patient presenting with chronic pain. Conditions that often have a neuropathic component include:
- Human Immune-deficiency virus (HIV)
- Phantom limb pain
- Diabetic neuropathies
- Peripheral neuropathies
- Central nervous system lesions (stroke, multiple sclerosis, spinal cord injury)
- Complex regional pain syndrome
- Chronic low back pain
Method of Use[edit | edit source]
LANSS: Contains 5 symptoms items and 2 clinical examination items. For the clinical examination, a cotton wool and 23 gauge needle is required. A score of 12 or above is indicative of predominantly neuropathic pain.
S-LANSS: A 7-item self-reported questionnaire without a clinical assessment component. It's accuracy is slightly improved when used in an interview format (rather than self-completed).
Evidence[edit | edit source]
Although some studies report good psychometric properties for the LANSS, a systematic review concluded that only the specificity of the LANSS is satisfactory. It is important to consider clinical judgement and clinical findings in combination with screening tools - screening tools fail to identify about 10-20% of patients with neuropathic pain.
LANSS[edit | edit source]
The LANSS has been tested and validated in several settings/conditions (including cancer pain and chronic low back pain)
S-LANSS[edit | edit source]
- Internal consistency and convergent validity was demonstrated with its development
- Sensitivity: Ranges from 52-78%
Additional Languages[edit | edit source]
- Turkish: The Turkish translation of the S-LANSS has been validated for use
- Greek, Portuguese, Spanish, Korean and Brazilian Portuguese versions have also been developed and tested in single studies - overall the psychometric properties of the translated versions were less than for the original versions.
Links[edit | edit source]
LANSS Pain Scale - English
S-LANSS Pain Score - English
References[edit | edit source]
- Bennett M. The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signs. Pain. 2001 May 1;92(1-2):147-57.
- Bennett MI, Smith BH, Torrance N, Potter J. The S-LANSS score for identifying pain of predominantly neuropathic origin: validation for use in clinical and postal research. The Journal of Pain. 2005 Mar 1;6(3):149-58.
- Mathieson S, Maher CG, Terwee CB, De Campos TF, Lin CW. Neuropathic pain screening questionnaires have limited measurement properties. A systematic review. Journal of clinical epidemiology. 2015 Aug 1;68(8):957-66.
- Bennett MI, Attal N, Backonja MM, Baron R, Bouhassira D, Freynhagen R, Scholz J, Tölle TR, Wittchen HU, Jensen TS. Using screening tools to identify neuropathic pain. Pain. 2007 Feb 1;127(3):199-203.
- Weingarten TN, Watson JC, Hooten WM, Wollan PC, Melton III LJ, Locketz AJ, Wong GY, Yawn BP. Validation of the S-LANSS in the community setting. Pain. 2007 Nov 1;132(1-2):189-94.
- Koc R, Erdemoglu AK. Validity and reliability of the Turkish Self-administered Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS) questionnaire. Pain Medicine. 2010 Jul 1;11(7):1107-14.
- Fagbohun TR. Systematic Review on the psychometric, reliability and validity properties of translated neuropathic pain screening tools (DN4, LANSS and PDQ) 1 January 2005 - 19 July 2019. International Journal of Medicine and Medical Research. 2021;7(1):51-67.